Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of HH-1270 in Healthy Chinese Participants
NCT07876440Phase 1Not yet recruiting
- Sponsor
- Huahui Health
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic hepatitis D comparing HH-1270 group with Placebo group (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events at 21 days and Clinically significant abnormalities at 21 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
HH-1270
03
Conditions
chronic hepatitis D
Beyond the preview
Go deeper on NCT07876440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876440.